Zacks: Brokerages Anticipate Aptose Biosciences Inc. (NASDAQ:APTO) Will Post Earnings of -$0.13 Per Share
Brokerages expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to post ($0.13) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Aptose Biosciences’ earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.12). Aptose Biosciences posted earnings per share of ($0.17) during the same quarter last year, which would suggest a positive year over year growth rate of 23.5%. The business is expected to announce its next quarterly earnings report on Tuesday, March 10th.
According to Zacks, analysts expect that Aptose Biosciences will report full-year earnings of ($0.53) per share for the current year, with EPS estimates ranging from ($0.55) to ($0.51). For the next year, analysts forecast that the business will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.70) to ($0.55). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Aptose Biosciences.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01.
Several large investors have recently modified their holdings of the business. Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Aptose Biosciences by 7.9% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 85,029 shares of the biotechnology company’s stock valued at $221,000 after acquiring an additional 6,200 shares during the period. Sigma Planning Corp boosted its holdings in shares of Aptose Biosciences by 4.1% in the 3rd quarter. Sigma Planning Corp now owns 228,150 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 9,000 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Aptose Biosciences by 20.7% in the 2nd quarter. Morgan Stanley now owns 315,521 shares of the biotechnology company’s stock worth $824,000 after purchasing an additional 54,200 shares in the last quarter. Gagnon Securities LLC purchased a new position in shares of Aptose Biosciences in the 2nd quarter worth about $146,000. Finally, Creative Planning purchased a new position in shares of Aptose Biosciences in the 3rd quarter worth about $156,000. 22.55% of the stock is currently owned by institutional investors.
APTO traded down $0.08 during trading on Tuesday, hitting $2.38. The company had a trading volume of 180,100 shares, compared to its average volume of 310,872. The company has a market cap of $137.05 million, a PE ratio of -2.77 and a beta of 1.64. The business has a 50-day moving average of $2.13 and a 200-day moving average of $2.29. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.83 and a quick ratio of 7.83. Aptose Biosciences has a 1-year low of $1.57 and a 1-year high of $3.13.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Story: Limitations of analyzing profit margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.